University of New Mexico
Welcome,         Profile    Billing    Logout  
 292 Trials 
386 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kelly, William K
NCT03047135: Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Active, not recruiting
2
51
US
Olaparib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca
Prostate
05/23
05/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT02555189: Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Completed
1/2
46
US
Enzalutamide, Xtandi, MDV3100, 915087-33-1, ASP9785, Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-, Ribociclib, LEE011, 1211441-98-3, 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, Kisqali, LEE-011, Laboratory Biomarker Analysis, Pharmacological Study, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Biopsy, BIOPSY_TYPE, Bx, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT SCAN, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, nuclear magnetic resonance imaging, sMRI, Structural MRI
Sidney Kimmel Cancer Center at Thomas Jefferson University, Novartis, Prostate Cancer Clinical Trials Consortium
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
12/22
09/23
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
Muller, Carolyn Y
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Recruiting
3
230
US
Cisplatin, Platinol AQ, No treatment
GOG Foundation, GlaxoSmithKline
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
08/29
08/34
GOG-3026, NCT03673124: Ribociclib and Letrozole Treatment in Ovarian Cancer

Active, not recruiting
2
51
US
Ribociclib, Letrozole
Gynecologic Oncology Group, Novartis
Low Grade Serous Carcinoma
12/23
12/24
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
NIR-OGT-201, NCT05348356 / 2022-001816-25: Nirogacestat in Ovarian Granulosa Cell Tumors

Active, not recruiting
2
53
Europe, Canada, US
Nirogacestat, PF-03084014
SpringWorks Therapeutics, Inc., SpringWorks Therapeutics, Inc.
Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer
07/26
12/27
KEYNOTE-B47, NCT04130516: Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab

Recruiting
1/2
200
US
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody, KEYTRUDA®, Pembrolizumab
Linnaeus Therapeutics, Inc., Merck Sharp & Dohme LLC
Solid Tumor, Adult
12/26
12/27
NCT06795009: Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Not yet recruiting
1
36
US
Zanzalintinib, XL092, Paclitaxel, Taxol
Washington University School of Medicine, National Cancer Institute (NCI), Exelixis
Uterine Cancer, Endometrial Cancer
06/29
11/34
NCT05826015: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Withdrawn
1
36
NA
Paclitaxel, Taxol, Batiraxcept, AVB-500
Washington University School of Medicine, National Cancer Institute (NCI), Aravive, Inc.
Recurrent High Grade Uterine Cancer
06/29
06/34
Sanchez, Pablo J
NCT06061081: A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Suspended
2
26
Europe, US, RoW
VH3739937, Placebo
ViiV Healthcare
HIV Infections
11/24
11/24
NCT04318587: Assessment of Donor Derived Cell Free DNA and Utility in Lung Transplantation

Terminated
N/A
40
US
Allosure
Pablo Sanchez, CareDx
Lung Transplant Failure and Rejection
12/22
12/23
Jansson, Lauren M
NCT06303986: Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process

Enrolling by invitation
N/A
60
US
Neomonki
Rekovar Inc., Johns Hopkins University, Children's Hospital of Orange County, Children's Hospital Los Angeles, University of New Mexico
Neonatal Abstinence Syndrome
06/25
06/25
Lee, Fa-Chyi
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
ASIST, NCT05322590: BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Active, not recruiting
1/2
195
US
BXQ-350, SapC-DOPS, Placebo
Bexion Pharmaceuticals, Inc., ICON plc, CTI Clinical Trial and Consulting Services
Metastatic Colorectal Carcinoma, Neuropathy
04/26
04/29
Starling, Randall
NCT03644667: Tocilizumab in Cardiac Transplantation

Active, not recruiting
2
385
US
tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone
National Institute of Allergy and Infectious Diseases (NIAID), PPD
Heart Transplant
04/25
04/25
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

Recruiting
N/A
300
Europe, US
Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication
Cardiac Dimensions, Inc.
Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases
12/26
12/30
Taylor, Karen
DECIDE CGM, NCT06490874: Continuous Glucose Monitoring (CGM) Substudy of the DECIDE RCT

Not yet recruiting
N/A
300
US
CGM device - Metformin group, CGM device - Insulin group
Ohio State University, The George Washington University Biostatistics Center, DexCom, Inc.
Gestational Diabetes Mellitus, Pregnancy, High Risk
12/29
12/30
Mutch, David G
NCT05829460: Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Not yet recruiting
2
96
US
Semaglutide, Placebo, LNG-IUD (Progestin), Telemedicine behavioral weight program
Washington University School of Medicine, Novo Nordisk A/S
Endometrial Hyperplasia
12/29
12/31
NCT05521997: Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Not yet recruiting
2
42
US
Telaglenastat, CB-893, Radiation treatment, Cisplatin
Washington University School of Medicine, National Cancer Institute (NCI), Calithera Biosciences, Inc
Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer, Cancer of the Cervix
04/31
04/31
NCT06795009: Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Not yet recruiting
1
36
US
Zanzalintinib, XL092, Paclitaxel, Taxol
Washington University School of Medicine, National Cancer Institute (NCI), Exelixis
Uterine Cancer, Endometrial Cancer
06/29
11/34
NCT03955978: TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Active, not recruiting
1
10
US
TSR-042, Brachytherapy, Endometrial biopsy, Blood draw for immune response
Washington University School of Medicine, Tesaro, Inc.
Endometrial Cancer, Cancer of the Endometrium
03/24
12/25
NCT05826015: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Withdrawn
1
36
NA
Paclitaxel, Taxol, Batiraxcept, AVB-500
Washington University School of Medicine, National Cancer Institute (NCI), Aravive, Inc.
Recurrent High Grade Uterine Cancer
06/29
06/34
Gupta, Ajay
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05706454: Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia

Recruiting
2/3
324
RoW
Ramatroban, BAYu3405, IUPAC Name: 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid, Placebo
KARE Biosciences, JSS Medical Research Inc., Biomedical Advanced Research and Development Authority, Open Philanthropy, Charak Laboratories India Pvt. Ltd, Charak Foundation, BioLink Life Sciences, Inc.
COVID-19 Pneumonia, COVID-19 Respiratory Infection
07/24
05/26
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
01/25
01/25
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting
1/2
21
US
Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
12/24
12/25
MASTER-2, NCT03933202: A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS

Active, not recruiting
N/A
295
US
Cladribine Tablets
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
05/25
05/25
Torbey, Michel
NCT02864953 / 2017-004854-41: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Terminated
3
535
Europe, Canada, Japan, US, RoW
BIIB093, glibenclamide, glibenclamide intravenous (IV), glyburide, CIRARA, Placebo
Remedy Pharmaceuticals, Inc.
Brain Edema, Stroke, Acute
08/23
08/23
ReMEDy2, NCT05065216: Treatment of Acute Ischemic Stroke ( Trial)

Recruiting
2/3
728
US
Recombinant human tissue kallikrein, DM199, Placebo for DM199 Solution for Injection
DiaMedica Therapeutics Inc
Acute Stroke, Ischemic Stroke, Stroke
12/26
12/26
Komesu, Yuko M
SUPeR, NCT01802281: Study of Uterine Prolapse Procedures - Randomized Trial

Active, not recruiting
N/A
183
US
Uterosacral ligament suspension, Uphold® LITE
NICHD Pelvic Floor Disorders Network, Boston Scientific Corporation
Uterovaginal Prolapse
07/23
10/24
Lee, Susan Shin-Jung
DEGS, NCT03678545: Dupilumab in Eosinophilic Gastritis

Active, not recruiting
2
41
US
Dupilumab (blinded), Placebo (blinded), Dupilumab (open-label)
Children's Hospital Medical Center, Cincinnati, Regeneron Pharmaceuticals, National Institutes of Health (NIH)
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
03/24
11/24
NCT06202521: CX-4945 in Viral Community Acquired Pneumonia

Recruiting
2
136
RoW
CX-4945 (SARS-CoV-2 domain), Silmitasertib, Placebo (SARS-CoV-2 domain), CX-4945 (Influenza virus domain), Placebo (Influenza virus domain)
Senhwa Biosciences, Inc.
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
03/25
06/25
Kinney, Anita Y
PINPOINT, NCT05034289: Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy

Completed
N/A
82
US
PINPOINT Digital Educational Tool
Rutgers, The State University of New Jersey, American Cancer Society, Inc., Pfizer
Clinical Trials, Immunotherapy
05/23
05/23
Hagemann, Andrea
NCT05829460: Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Not yet recruiting
2
96
US
Semaglutide, Placebo, LNG-IUD (Progestin), Telemedicine behavioral weight program
Washington University School of Medicine, Novo Nordisk A/S
Endometrial Hyperplasia
12/29
12/31
NCT05521997: Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Not yet recruiting
2
42
US
Telaglenastat, CB-893, Radiation treatment, Cisplatin
Washington University School of Medicine, National Cancer Institute (NCI), Calithera Biosciences, Inc
Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer, Cancer of the Cervix
04/31
04/31
NCT06795009: Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Not yet recruiting
1
36
US
Zanzalintinib, XL092, Paclitaxel, Taxol
Washington University School of Medicine, National Cancer Institute (NCI), Exelixis
Uterine Cancer, Endometrial Cancer
06/29
11/34
NCT03955978: TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Active, not recruiting
1
10
US
TSR-042, Brachytherapy, Endometrial biopsy, Blood draw for immune response
Washington University School of Medicine, Tesaro, Inc.
Endometrial Cancer, Cancer of the Endometrium
03/24
12/25
NCT05826015: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Withdrawn
1
36
NA
Paclitaxel, Taxol, Batiraxcept, AVB-500
Washington University School of Medicine, National Cancer Institute (NCI), Aravive, Inc.
Recurrent High Grade Uterine Cancer
06/29
06/34
Richardson, Sarah Pirio
NCT05411848: 2kcal Tube Feed Study

Completed
N/A
42
Europe
2kcal HP PlantBased
Nutricia UK Ltd
Enteral Nutrition, Cancer
12/23
12/23
Meriwether, Kate V
NCT04772131: Desara ® One Single Incision Sling 522 Study

Recruiting
N/A
300
US
Desara® One Single Incision Sling, Desara® Blue Transobturator Sling
Caldera Medical, Inc.
Stress Urinary Incontinence
11/26
11/26
Shaheen, Montaser
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
230
US, RoW
Phase 1b: APG-115+pembrolizumab, KEYTRUDA®
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
12/24
03/25
NCT06035744: CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
1
86
US
CLN-617, Pembrolizumab, Keytruda
Cullinan Therapeutics Inc.
Advanced Solid Tumor
06/28
06/28
Gustot, Thierry
PRECIOSA, NCT03451292 / 2016-001789-28: Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites

Completed
3
410
Europe, Canada, US, RoW
Albutein 20% Injectable Solution, Standard medical treatment
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Decompensated Cirrhosis and Ascites
05/24
05/24
APACHE, NCT03702920 / 2016-001787-10: Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Recruiting
3
380
Europe, US
SMT + PE-A 5%, Albutein 5%, Standard Medical Treatment, SMT
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Acute-On-Chronic Liver Failure
10/26
10/26
DHELIVER, NCT04229901: Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)

Terminated
2
133
Europe, RoW
HepaStem, Placebo
Cellaion SA
Acute on Chronic Liver Failure
05/24
05/24
LIBERATE, NCT05234190 / 2021-001379-18: Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

Recruiting
1/2
33
Europe
QEL-001, HLA-A2 CAR-Treg
Quell Therapeutics Limited, Quell Therapeutics Limited
Rejection; Transplant, Liver, Liver Failure, Liver Diseases
09/25
03/40
Crandall, Cameron
NCT04225598: Emergency Department-Initiated Buprenorphine Validation Network Trial

Completed
2
2000
US
CAM2038, Buprenorphine Sublingual Product
Yale University, National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, Harvard Medical School (HMS and HSDM), University of Pennsylvania, NYU Langone Health, Icahn School of Medicine at Mount Sinai, Alameda Health System, Weill Medical College of Cornell University, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
12/24
12/24
Patel, Ravi
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Recruiting
3
70
US
RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control
ReGenTree, LLC
Neurotrophic Keratopathy
07/24
11/24
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
560
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
NCT05655312: MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Recruiting
1/2
264
US
[203Pb]VMT01, [212Pb]VMT01, Nivolumab
Perspective Therapeutics
Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
12/27
12/29
NeoRay, NCT03872778 / 2018-004727-37: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake

Recruiting
1/2
51
Europe, US
[177Lu]-NeoB, Lutetium NeoB, [68Ga]-NeoB, Gallium NeoB, LCZ696, sacubitril/valsartan
Advanced Accelerator Applications, Advanced Accelerator Applications International SA
Neoplasms
11/25
12/26
Rebalance-HF, NCT04592445: Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Recruiting
N/A
80
US
Satera GSN Ablation, Sham Control
Axon Therapies, Inc.
Heart Failure With Preserved Ejection Fraction
04/22
03/23
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
CONCERTO, NCT05438732: Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

Recruiting
N/A
125
US
smaller incision, new generation implantable miniature telescope (SING-IMT)
VisionCare, Inc., ORA, Inc.
Age-Related Macular Degeneration, Geographic Atrophy
12/25
12/25
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
Carlson, Andrew
ENCASE II, NCT04086550: Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery

Completed
N/A
228
Europe, US
LIQOSEAL, DuraSeal, Adherus
Polyganics BV
Cerebrospinal Fluid Leak
02/24
02/24
Brown-Glaberman, Ursa
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
DARE, NCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Recruiting
2
70
US
Palbociclib, IBRANCE, Fulvestrant, Faslodex, Adjuvant Therapy, Standard of Care
Criterium, Inc.
Breast Cancer
12/27
12/27
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
12/27
12/28
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Active, not recruiting
1/2
41
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
07/24
10/25
Shafer, Stuart
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
Thompson, Jennifer
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
NCT05113966: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Checkmark Data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Data from P2 trial for locally advanced or metastatic TNBC
Checkmark Presentation of data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Presentation of data from P2 trial for locally advanced or metastatic TNBC
Terminated
2
30
US
Trilaciclib, G1T28, CDK 4/6 inhibitor, Sacituzumab Govitecan-hziy, Trodelvy, IMMU-132
G1 Therapeutics, Inc.
Triple Negative Breast Cancer
11/23
06/24
NCT06564753: Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition

Recruiting
2
125
RoW
Drug: Placebo daily and orally, NA-931 placebo, NA-931, dose 1, daily and orally, NA-931, NA-931, dose2, daily and orally, NA-931 dose 3, daily and orally, NA=931, NA-931 dose 4, daily and orally
NeuroActiva, Inc., Biomed Industries, Inc.
Weight Loss, Obesity, Body Weight, Body Weight Changes
01/25
02/25
NA-931-200, NCT06732245: Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Not yet recruiting
2
224
US, RoW
NA-931, Tirzepatide placebo, Tirzepatide, NA-931 Placebo, NA-931 150 mg + no Tirzepatide
Biomed Industries, Inc., Bioneurals Ltd
Obesity and Overweight
08/26
12/26
Acclaim-3, NCT05703971: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Recruiting
1/2
62
US
quaratusugene ozeplasmid, REQORSA, atezolizumab, TECENTRIQ
Genprex, Inc.
Small Cell Lung Cancer Extensive Stage
02/26
08/27
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting
1
108
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
12/24
12/24
Dilling, Daniel
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active, not recruiting
3
160
Europe, Canada, Japan, US, RoW
Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo
Savara Inc., Savara ApS,
Autoimmune Pulmonary Alveolar Proteinosis
11/23
11/24
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
IPF COMFORT, NCT05185089 / 2021-006278-22: Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

Completed
2
80
Europe, US
Orvepitant Maleate, Placebo
Nerre Therapeutics Ltd., Pharm-Olam International
Cough, Idiopathic Pulmonary Fibrosis
06/24
06/24
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Active, not recruiting
2
99
Europe, US, RoW
SAR447537, Zemaira, Respreeza
Sanofi
Alpha 1-Antitrypsin Deficiency, Emphysema
08/25
10/25
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Active, not recruiting
2
129
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
01/25
09/25
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
ALAMO, NCT05050955: AlloSure Lung Assessment and Metagenomics Outcomes Study

Recruiting
N/A
500
Canada, US
CareDx
Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
12/28
12/28
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Checkmark
Oct 2015 - Oct 2015: 
Recruiting
N/A
3000
US
Duke University, Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
01/28
01/28
Woodall, Gill
B-SMART, NCT03828370: DWI Offenders and Their Families App for Smartphones

Completed
N/A
246
US
B-SMART Intervention Group, Usual and Customary Information Group
Klein Buendel, Inc., University of New Mexico, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Coping Skills, Family Relations
03/23
03/23
NCT05779774: WayToServePlus: Improving Responsible Alcohol Service Ph II

Recruiting
N/A
1172
US
WayToServe Plus In-service Component, WayToServe Training Only
Klein Buendel, Inc., National Institute on Alcohol Abuse and Alcoholism (NIAAA), Pacific Institute for Research and Evaluation
Alcohol Drinking, Alcohol Intoxication, Alcohol Use, Unspecified
03/25
05/25
NCT06235632: Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers

Not yet recruiting
N/A
229
US
Policy and Training Intervention, Usual and Customary Policy and Training (UC-PT) (Control) Condition
Klein Buendel, Inc., National Institute on Alcohol Abuse and Alcoholism (NIAAA), Pacific Institute for Research and Evaluation, National Opinion Research Center
Alcoholic Intoxication, Automobile Accident, Cannabis
03/27
08/27
Battarbee, Ashley N
DECIDE CGM, NCT06490874: Continuous Glucose Monitoring (CGM) Substudy of the DECIDE RCT

Not yet recruiting
N/A
300
US
CGM device - Metformin group, CGM device - Insulin group
Ohio State University, The George Washington University Biostatistics Center, DexCom, Inc.
Gestational Diabetes Mellitus, Pregnancy, High Risk
12/29
12/30
Argyropoulos, Christos
TRIDENT, NCT02986984: Transformative Research in Diabetic Nephropathy

Recruiting
N/A
400
US
There is no intervention, There are no interventions
University of Pennsylvania, MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S
Diabetic Nephropathies, Diabetic Glomerulosclerosis
01/25
06/25
Raval, Jay
APACHE, NCT03702920 / 2016-001787-10: Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Recruiting
3
380
Europe, US
SMT + PE-A 5%, Albutein 5%, Standard Medical Treatment, SMT
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Acute-On-Chronic Liver Failure
10/26
10/26
Fero, Matthew
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
MPCT-012L, NCT05826535: Study of IMPT-314 in R/R Aggressive B-cell NHL

Recruiting
1/2
150
US
IMPT-314
ImmPACT Bio
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
06/25
12/29
Martinez, Carlos E
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
320
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
NCT05272865: Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC

Not yet recruiting
1/2
334
RoW
Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator, Administration of different Cannabis oral formulations with THC as compared with Active comparator (DRONABINOL)
LaSanta S A S
Nausea Post Chemotherapy, Vomiting, Cancer Pain, Cancer Related Pain, Neoplasms
02/24
10/24
NCT03011554: Telescope Exchange Study

Recruiting
N/A
75
US
Implantable Miniature Telescope (IMT)
VisionCare, Inc.
Age-related Macular Degeneration
12/19
12/22
TRIDENT, NCT02986984: Transformative Research in Diabetic Nephropathy

Recruiting
N/A
400
US
There is no intervention, There are no interventions
University of Pennsylvania, MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S
Diabetic Nephropathies, Diabetic Glomerulosclerosis
01/25
06/25
 

Download Options